Health Rounds: Semaglutide pill Rybelsus matches heart benefits of injectable versions
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
PharmExec4d
Rybelsus Found to Significantly Reduce Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes, Cardiovascular Disease
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...
News-Medical.Net on MSN4d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Fierce Pharma5d
FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
BioSpace5d
Novo Paints Murky Cardio Picture for Semaglutide Franchise
According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...
Becker's Hospital Review5d
Rybelsus reduces cardiovascular event risk in late stage trial: Study
Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney disease, ...
Explore more
PipelineReview.com6d
Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ...
The Scientist3h
Scientists Who Pioneered GLP-1 Drugs Bag Breakthrough Prize
Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...
Novo Nordisk Stock (NVO) Drops Despite Positive GLP-1 Trial Data
Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus.
News Medical5d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse ...